Des R. Richardson
Des R. Richardson is an NHMRC Senior Principal Research Fellow, University of Sydney, Sydney, Australia. He received his B.S., M.S., Ph.D., and D.S. degrees. He is internationally an expert in the field of iron metabolism of tumor cells and the development of iron chelators for clinical use. Richardson is a leader of the Bosch Institute Prostate Cancer Focus Group, and he has published more than 285 research articles, chapters, and reviews, mostly as the first or senior/corresponding author. Richardson has been invited to write many reviews, editorials/perspectives, and Leading Edge preview articles for top shelf journals (e.g., Cell, Lancet, Pharmacol Reviews, BLOOD, and PNAS USA). Richardson’s major contributions to cancer research are focused on understanding the role of iron in cancer cell proliferation and the development of novel antitumor agents known as iron chelators. These studies have resulted in promising and potent anticancer drugs and are subject of a suite of active national patents. He has identified that the important prostate cancer growth and metastasis suppressor NDRG1 is regulated by iron and is an important target of a new class of drugs being developed in his lab. He also studies the role of alpha-2-macroglobulin in the transport and uptake of the iron metabolism regulatory hormone hepcidin. He researches the role of frataxin and has been actively involved in development of treatments for Friedreich’s ataxia.
Biography Updated on 6 December 2012